Skye Bioscience Inc (SKYE)

[Vinpat]

I don think anyone wants a suppository unless you need it. Nemus seems to be avoiding anything that has to go through the liver as is Zynerba. They both seem to be concerned about the efficacy of an oral drug which has merit. We'll see how GWPH does with Epidiolex but Sativex isn't very effective. There are better options on the street.

It has been quiet but I would bet they'll be making announcements on an alignment with an investment bank, uplisting and partnerships that will drive up the price. They have more valuable IP than GW and Zynerba it just comes down to execution. I think they will execute with the group they have.